Silvio Edward Inzucchi MD

PubMed

• Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A ...
  Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui, John Deanfield, Scott S Emerson
  Diabetes Care. 2025-05-01
• Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease.
  John W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, Zi Michael Miao, Silvio E Inzucchi
  European Heart Journal. 2025-04-07
• 3 citations
  Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
  Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Lawrence A Leiter
  The Lancet. Diabetes & Endocrinology. 2025-04-01

Journal Articles

• Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial  
  Silvio Inzucchi, MD, Journal of the American Society of Nephrology
• Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
  Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
• Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
  Christina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine

Lectures

• Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
  American Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
• Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
  Scientific Sessions 2008, New Orleans, Louisiana, USA
• Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
  Scientific Sessions 2010, Chicago, Illinois, USA
• Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
  American Heart Association, Scientific Sessions 2008, New Orleans, Louisiana, USA
• Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
  New Haven, CT - 6/15/2014
• Join now to see all

Other

• Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers 
  Silvio Inzucchi, MD, Diabetes, Obesity and Metabolism
  https://www.doximity.com/articles/b552b1a0-ea89-475a-8388-913374468095
  UpToDate, Wolters Kluwer Health - 2012-07-30
• Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus 
  Silvio Inzucchi, MD, Annals of Internal Medicine
  https://www.doximity.com/articles/dea6d159-a396-4c8a-8d46-4b009fecfb26
  UpToDate, Wolters Kluwer Health - 2012-05-24